Valbenazine (Ingrezza)

What it treats

Valbenazine is approved by the U.S. Food and Drug Administration for tardive dyskinesia in adults and, in a more recent label expansion, for chorea associated with Huntington disease, including a 2024 pediatric indication for Huntington chorea.

Tardive dyskinesia is the involuntary movement disorder that can develop after months to years of exposure to antipsychotics or other dopamine-blocking medications like metoclopramide. The face, mouth, and tongue are the most common sites, but the trunk and limbs can be involved. Huntington chorea is the ongoing, involuntary movement piece of Huntington disease.

How it works

Valbenazine blocks the vesicular monoamine transporter type 2 (VMAT2). VMAT2 is a small pump on the storage sacs inside monoamine nerve terminals; it's what loads dopamine into the packets that get released when the nerve fires. Block the loading step, less dopamine is available to release, and the overactive movement signals in TD and Huntington chorea get quieter.

The active piece of valbenazine is a metabolite called (+)-alpha-HTBZ. That metabolite has a relatively long half-life, which is why the drug can be dosed once a day.

Receptor mechanism (detail)

Valbenazine inhibits the vesicular monoamine transporter type 2 (VMAT2), reducing the presynaptic loading of dopamine (and to a smaller degree serotonin and norepinephrine). The parent drug is a prodrug; the sustained effect comes from its active metabolite (+)-alpha-dihydrotetrabenazine, which is more selective for VMAT2 than the parent and has a half-life that supports once-daily dosing.

Potency and typical dosing pattern

Ranges are typical framework only, not a prescription for any individual.

Standard start is 40 mg once daily for the first week, then increase to 80 mg once daily. Some patients get a good response at 40 mg and can stay there. Others land at 60 mg. The 80 mg dose is the usual therapeutic target for TD.

CYP2D6 poor metabolizers and patients on strong CYP3A4 inhibitors should stay at 40 mg maximum. Strong CYP3A4 inducers (like rifampin, carbamazepine) can lower valbenazine levels enough that co-administration isn't recommended.

Safety monitoring

• QTc on ECG in patients with cardiovascular risk factors or on other QT-prolonging medications.
• Mood, depression, and suicidal thoughts. The signal exists across VMAT2 inhibitors, and the Huntington disease population carries the clearest risk.
• Somnolence early in treatment, especially with driving.
• Parkinsonism and akathisia, which can look like TD returning if you don't know to check for them.
• Liver function in patients with hepatic impairment; dose adjustment is required in moderate to severe cases.

What to expect

Some patients notice a reduction in movements in the first two weeks, but the fuller effect usually settles in over four to six weeks at the target dose. TD is variable day to day, so the trend over weeks is what matters, not any single day.

Somnolence, if it shows up, is usually noticeable early and tends to ease as the body adjusts. Timing the dose (morning versus evening) can be adjusted to work with whatever pattern helps most.

Common side effects

Most people tolerate valbenazine reasonably well. The ones reported most often include:

• Somnolence.
• Fatigue.
• Headache.
• Dry mouth.
• Constipation.
• Balance disturbance or a slightly slowed feeling.
• Akathisia (a restless, need-to-move sensation).

Many of these fade over the first few weeks. If a side effect is dose-related, a small pull-back often helps.

Serious side effects and warnings

Serious problems are uncommon, but a few need to be understood before starting.

• QT prolongation. Valbenazine can lengthen QTc, especially in CYP2D6 poor metabolizers or when combined with other QT-prolonging medications. Baseline and follow-up ECGs are reasonable in higher-risk patients.
• Depression and suicidal thinking. The label for the TD indication doesn't carry the same boxed warning as tetrabenazine, but the mechanism is shared and mood should be tracked. In Huntington disease, the depression signal is more established.
• Parkinsonism and akathisia. Because the drug depletes dopamine, it can produce the very movement side effects that antipsychotics cause. Dose adjustment usually helps.
• Somnolence and impaired driving, particularly during titration.

Sexual and relational effects

Valbenazine isn't a leading cause of sexual side effects. Some patients report reduced desire, likely tied to sedation or dopamine depletion. If sexual function shifts after starting it, that's worth raising with the prescriber.

Weight, appetite, and sleep

Weight and appetite aren't strongly affected. Sleep can be somewhat sedating; a few patients notice mild insomnia instead. Adjusting the time of day the dose is taken usually settles that.

Starting and dosing basics

This section is general background, not a dosing instruction for any individual. The right dose is a decision for a prescriber.

Valbenazine comes as 40, 60, and 80 mg capsules, taken once daily with or without food. There's also an oral granules formulation for patients who can't swallow capsules or need enteral feeding tube administration. The dose can be taken at any consistent time of day.

Missed doses and interactions

If you miss a dose, take it as soon as you remember unless the next scheduled dose is close. Don't double up.

The main interactions:

• Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) raise valbenazine levels; the max dose drops to 40 mg.
• Strong CYP3A4 inducers (rifampin, carbamazepine, St. John's wort) lower levels enough that combination isn't recommended.
• CYP2D6 poor metabolizers also stay at 40 mg maximum.
• MAO inhibitors shouldn't be combined.
• QT-prolonging drugs need caution.
• Alcohol adds to sedation.

Give every prescriber and pharmacist a full list of your medications and supplements.

Stopping and tapering

Valbenazine can be stopped without a formal taper. Tardive dyskinesia or Huntington chorea will typically return over days to weeks after stopping. If a break is planned, the return of movements should be expected and worked through with the prescriber ahead of time.

Pregnancy and breastfeeding

Data in pregnancy is limited. Use is generally reserved for cases where the movement disorder is functionally significant. Whether the drug or its active metabolite passes into breast milk in meaningful amounts isn't well established. Anyone who is pregnant, planning a pregnancy, or breastfeeding should talk it through with their prescriber so specific risks and benefits can be weighed.

Cost and generic availability

Valbenazine is brand-only (Ingrezza) and expensive. There's no generic as of this review date. Manufacturer patient assistance and specialty pharmacy handling are usually involved. Insurance approval typically requires documentation of the TD or Huntington chorea diagnosis and, for TD, some record of prior antipsychotic exposure.

Common questions

How is this different from deutetrabenazine? Both are VMAT2 inhibitors. Valbenazine is once-daily; deutetrabenazine is twice-daily immediate-release or once-daily extended-release. Their side-effect profiles are similar. Choice often comes down to insurance coverage, tolerability, and dosing preference.

Will my TD movements come back if I stop? Usually yes, over days to weeks. VMAT2 inhibitors treat the movements; they don't reverse the underlying condition.

Do I have to stop my antipsychotic? Usually not. Many patients continue an antipsychotic for a primary psychiatric condition while taking valbenazine. Whether the antipsychotic can be lowered or switched to a lower-TD-risk agent is a separate conversation with the prescriber.

Why does dose max out at 40 mg for some people? CYP2D6 poor metabolizers and people on strong CYP3A4 inhibitors clear the drug more slowly, so the 80 mg dose builds up too much. The 40 mg cap keeps blood levels in a safer range.

Questions to ask your prescriber

• What are we hoping this treats, and how will we know it's working?
• Should I have an ECG before or during treatment, given my other medications?
• What signs of mood change or depression should trigger a call?
• Do any of my current medications require a lower dose ceiling?
• If it doesn't work well enough at 80 mg, what are the next options?

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes, and current as of June 8, 2026.

• U.S. Food and Drug Administration. Valbenazine (Ingrezza) prescribing information.
• DailyMed, U.S. National Library of Medicine. Valbenazine label.
• MedlinePlus, U.S. National Library of Medicine. Valbenazine.
• National Institute of Mental Health. Mental health medications.
• American Academy of Neurology. Tardive syndromes treatment guideline.
• Huntington Study Group. Recommendations on the use of VMAT2 inhibitors for chorea in Huntington disease.